Latest Articles

Publication Date
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients - Labroots

Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients Labroots

Published: Oct. 16, 2025, 10 a.m.
Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer - OncLive

Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer OncLive

Published: Oct. 15, 2025, 5:46 p.m.
Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer - OncLive

Rucaparib Maintenance Therapy Displays Activity in Pretreated Recurrent/Metastatic Endometrial Cancer OncLive

Published: Oct. 15, 2025, 12:10 p.m.
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - Bioengineer.org

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival Bioengineer.org

Published: Oct. 14, 2025, 4:49 p.m.
Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival - BIOENGINEER.ORG

Immunotherapy Plus Chemotherapy Boosts Endometrial Cancer Survival BIOENGINEER.ORG

Published: Oct. 14, 2025, 4:49 p.m.
Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer - Nature

Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer Nature

Published: Oct. 14, 2025, 4:47 p.m.
Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials - BMC Cancer

Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials BMC Cancer

Published: Oct. 14, 2025, 2:41 p.m.
‘Invisible diseases’ burden both body and mind. Can therapy help? - Psyche

‘Invisible diseases’ burden both body and mind. Can therapy help? Psyche

Published: Oct. 14, 2025, 10 a.m.
Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer - CancerNetwork

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer CancerNetwork

Published: Oct. 13, 2025, 10:05 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!